PS-Gene Therapy for Inherited Retinal Dystrophies - The Present & Future
Description:
The 2017 FDA approval of the first gene therapy for a genetic disease in the United States marked the beginning of a new chapter in the practice of medicine. This breakthrough has changed the future of counseling and management for patients with inherited retinal dystrophies, such as retinitis pigmentosa and Leber congenital amaurosis. As the field of gene therapy grows and as more patients qualify for available gene therapies and clinical trials, optometrists are needed to help with education, identification, and referral of patients who may benefit from the surge of innovative research and therapies. This course presentation and discussion will cover the current state of ocular gene therapy and gene therapy research. Particular emphasis will be placed on FDA approved gene therapy eligibility and outcomes. We will provide an overview of current clinical trials, including developments in CRISPR gene editing and antisense oligonucleotide-based therapy. We will cover common patient questions and answers regarding gene therapy and genetic testing. We will address the current clinical guidelines for genetic testing and the incorporation of genetic testing into clinical practice. Patient and practitioner resources will be presented, including online patient registry and clinical trial resources.
Course Code:
AOA174-PS
Speaker(s):
Rachelle Lin, O.D.
rachelle.lin@gmail.com
Credits:
1
AOA Expiration Date:
8/27/2024
Lawmakers host AOA, patient and consumer advocates for VBM abuse briefing as Congress expands probes
At the request of a key U.S. House committee, AOA and patient and consumer advocates briefed lawmakers and staff on growing vision benefit manager (VBM) abuses as Capitol Hill leaders increasingly probe their costly, controlling and care-limiting schemes.
Are you ready for the Eyeglass Rule of 2024?
The Federal Trade Commission issued its updated Eyeglass Rule after an extended review. The rule, which takes effect Sept. 24, requires doctors of optometry to get patient confirmation that they had received a copy of their prescription at the completion of an eye exam.
On the radar: Emerging technologies
The AOA’s New Technology Committee shares five areas they are investigating and how they might affect your practice.